2024-03-28T14:45:13Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_CAA77BE7C76D
2024-03-23T02:58:53Z
serval:BIB_CAA77BE7C76D
Thalidomide in patients with advanced multiple myeloma
10.1038/sj/thj/6200031
11920188
I.
Yakoub-Agha
author
P.
Moreau
author
S.
Leyvraz
author
C.
Berthou
author
C.
Payen
author
C.
Dumontet
author
B.
Grosbois
author
P.
Beris
author
C.
Duguet
author
M.
Attal
author
J. L.
Harousseau
author
T.
Facon
author
article
2000
Hematology Journal
1466-4860
journal
1
3
186-9
Agranulocytosis/chemically induced
Angiogenesis Inhibitors/adverse effects/*therapeutic use
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Immunoglobulin A/blood
Immunoglobulin G/blood
Immunoglobulin Isotypes/blood
Immunoglobulin Light Chains/blood
Male
Multiple Myeloma/blood/*drug therapy/immunology/pathology
Thalidomide/adverse effects/*therapeutic use
Time Factors
Treatment Outcome
Clinical Trial
Journal Article
Multicenter Study
60_published